Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 24835058)

1.

Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis.

Garg T, Pinheiro LC, Atoria CL, Donat SM, Weissman JS, Herr HW, Elkin EB.

J Urol. 2014 Oct;192(4):1072-7. doi: 10.1016/j.juro.2014.04.101. Epub 2014 May 14.

PMID:
24835058
2.

Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation.

Cohn JA, Vekhter B, Lyttle C, Steinberg GD, Large MC.

Cancer. 2014 Feb 15;120(4):555-61. doi: 10.1002/cncr.28416. Epub 2013 Nov 13.

3.

Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer?

Henning A, Wehrberger M, Madersbacher S, Pycha A, Martini T, Comploj E, Jeschke K, Tripolt C, Rauchenwald M.

BJU Int. 2013 Jul;112(1):68-73. doi: 10.1111/j.1464-410X.2012.11661.x. Epub 2013 Jan 15.

PMID:
23320798
4.

Can hematuria be a predictor as well as a symptom or sign of bladder cancer?

Friedman GD, Carroll PR, Cattolica EV, Hiatt RA.

Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):993-6.

5.

Patterns of hematuria referral to urologists: does a gender disparity exist?

Johnson EK, Daignault S, Zhang Y, Lee CT.

Urology. 2008 Sep;72(3):498-502; discussion 502-3. doi: 10.1016/j.urology.2008.01.086. Epub 2008 Jul 10.

PMID:
18619657
6.

Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer.

Cha EK, Tirsar LA, Schwentner C, Hennenlotter J, Christos PJ, Stenzl A, Mian C, Martini T, Pycha A, Shariat SF, Schmitz-Dräger BJ.

World J Urol. 2012 Dec;30(6):847-52. doi: 10.1007/s00345-012-0979-x. Epub 2012 Nov 5.

7.

Prospective external validation of a bladder cancer detection model.

Lotan Y, Svatek RS, Krabbe LM, Xylinas E, Klatte T, Shariat SF.

J Urol. 2014 Nov;192(5):1343-8. doi: 10.1016/j.juro.2014.05.087. Epub 2014 May 21.

PMID:
24859442
8.

Can reproductive characteristics predict bladder cancer in women with haematuria?

Yavuzcan A, Caglar M, Kayikci MA, Basaran E, Tekin A, Ozdemir E, Dilbaz S, Ustun Y, Cam HK.

Asian Pac J Cancer Prev. 2013;14(9):5107-10.

9.

General adherence to guideline recommendations on initial diagnosis of bladder cancer in the United States and influencing factors.

Karl A, Adejoro O, Saigal C, Konety B; Urologic Diseases in America Project.

Clin Genitourin Cancer. 2014 Aug;12(4):270-7. doi: 10.1016/j.clgc.2013.11.003. Epub 2013 Nov 14.

PMID:
24332507
10.

Adherence to surveillance among patients with superficial bladder cancer.

Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB.

J Natl Cancer Inst. 2003 Apr 16;95(8):588-97.

11.

Epidemiologic and socioeconomic status of bladder cancer in Mazandaran Province, northern Iran.

Ahmadi M, Ranjbaran H, Amiri MM, Nozari J, Mirzajani MR, Azadbakht M, Hosseinimehr SJ.

Asian Pac J Cancer Prev. 2012;13(10):5053-6.

12.

Mammography use, breast cancer stage at diagnosis, and survival among older women.

McCarthy EP, Burns RB, Freund KM, Ash AS, Shwartz M, Marwill SL, Moskowitz MA.

J Am Geriatr Soc. 2000 Oct;48(10):1226-33.

PMID:
11037009
13.

Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.

Blick CG, Nazir SA, Mallett S, Turney BW, Onwu NN, Roberts IS, Crew JP, Cowan NC.

BJU Int. 2012 Jul;110(1):84-94. doi: 10.1111/j.1464-410X.2011.10664.x. Epub 2011 Nov 28.

PMID:
22122739
14.

Causes of death and relative survival of older women after a breast cancer diagnosis.

Schonberg MA, Marcantonio ER, Ngo L, Li D, Silliman RA, McCarthy EP.

J Clin Oncol. 2011 Apr 20;29(12):1570-7. doi: 10.1200/JCO.2010.33.0472. Epub 2011 Mar 14. Erratum in: J Clin Oncol. 2011 Sep 10;29(26):3594.

15.

Hematuria screening test for urinary bladder mucosal infiltration in cervical cancer.

Chuttiangtum A, Udomthavornsuk B, Chumworathayi B.

Asian Pac J Cancer Prev. 2012;13(10):4931-3.

16.

Recurrence of high-risk bladder cancer: a population-based analysis.

Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS; Urologic Diseases in America Project.

Cancer. 2013 Sep 1;119(17):3219-27. doi: 10.1002/cncr.28147. Epub 2013 Jun 4.

17.

Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.

Bangma CH, Loeb S, Busstra M, Zhu X, El Bouazzaoui S, Refos J, Van Der Keur KA, Tjin S, Franken CG, van Leenders GJ, Zwarthoff EC, Roobol MJ.

Eur Urol. 2013 Jul;64(1):41-7. doi: 10.1016/j.eururo.2013.02.036. Epub 2013 Mar 4.

PMID:
23478169
18.

The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuria.

Trojan B, Tang A, Chandrapal J, Filleur S, Nelius T.

Ren Fail. 2013;35(1):72-6. doi: 10.3109/0886022X.2012.741648. Epub 2012 Nov 14.

PMID:
23151051
19.

The burden of bladder cancer in men and women: analysis of the years of life lost.

Scosyrev E, Golijanin D, Wu G, Messing E.

BJU Int. 2012 Jan;109(1):57-62. doi: 10.1111/j.1464-410X.2011.10318.x. Epub 2011 Aug 23.

PMID:
21883817
20.

The risk of bladder cancer in patients diagnosed with other primary neoplasms: analysis of the SEER database.

Anderson JK, Alanee S, Lindgren B, Slaton J.

Urol Oncol. 2013 Aug;31(6):862-5. doi: 10.1016/j.urolonc.2011.06.005. Epub 2011 Jul 23.

PMID:
21784673
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk